Drugs / SYNB8802v1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05377112 | Mar → Dec 2022 | — | Synlogic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYNB8802v1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05377112 ↗ |
| Modality | Other / unclassified | “SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH.” NCT05377112 ↗ |
| Route | Oral | “SYNB8802v1 is an orally administered” NCT05377112 ↗ |